Catalent seeks slice of gene therapy market with Paragon buy
(Reuters) – Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs…